“Over 55 million people around the world live with dementia, and as the global population ages, that number is expected to nearly triple by 2050. Alzheimer’s disease, the most common form of dementia, accounting for an estimated 60 to 70% of cases, is a neurodegenerative disorder characterized by the accumulation of amyloid plaques and tau neurofibrillary tangles that leads to memory loss and a decline in cognitive abilities so significant, it interferes with daily life and ultimately results in death.

For more than three decades, Johnson & Johnson scientists have been working to better understand the complex biology of Alzheimer’s disease and pioneer new ways to treat it. Today, it’s recognized as a progressive continuum that begins silently with the accumulation of amyloid and tau in the brain, often years before symptoms appear. ”

Now, the company is closer than ever to reaching three significant goals in the fight against Alzheimer’s disease.”

*Both Plaques and Tangles are present in the brains of individuals without Alzheimer’s; however, they are found at much higher levels in the brains of Alzheimer’s patients.

​It is theorized that the root causes of Alzheimer’s disease are the factors which control the amount of Amyloid and Tau in the brain. Factors like the ApoE gene.  These are 2 plaques damaging brain cells and cause the brain lesions characteristic of Alzheimer’s disease.*

Johnson and Johnson (How J&J is advancing the fight against Alzheimer’s disease )